Researchers at Vanderbilt University Medical Center have isolated human monoclonal antibodies against influenza B, a virus that disproportionately affects high-risk groups. Current flu vaccines do not provide broad immune responses against both influenza A and B, making additional treatment options necessary. The researchers found two groups of antibodies that effectively target the neuraminidase glycoprotein of influenza B, with one antibody, FluB-400, showing promise in preventing infection in lab and animal studies. The development of these antibodies could lead to improved treatments for influenza B and help guide efforts to create a universal influenza vaccine.
Source link
Antibody discovery promises new hope in influenza B battle, paves way for universal vaccine
